Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	inclusion criteria: * secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) * on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode) or no current treatment * no recent treatment changes	inclusion criteria: * secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) * on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode) or no current treatment * no recent treatment changes
May 18, 2024, 8 a.m.	usa	inclusion criteria: secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode) or no current treatment no recent treatment changes	inclusion criteria: secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode) or no current treatment no recent treatment changes
March 13, 2021, 12:31 a.m.	usa	inclusion criteria: - secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) - on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode or no current treatment) - no recent treatment changes	inclusion criteria: - secondary progressive multiple sclerosis (spms) diagnosis or with relapsing remitting multiple sclerosis (rrms) at risk to develop spms (at the discretion of the treating physician) - on stable ms treatment (siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode or no current treatment) - no recent treatment changes